While PARP inhibitors use in BRCA1/2 mutated tumors remains the best characterized treatment based on synthetically lethality, numerous other synthetic lethal interactions have been identified using RNAi screens, based on other mutations found in lung cancer, including mKRAS and EGFR mutations [summarized in (115)]. This evidence concerns the gene PARP1 and lung cancer.